U.S. Ultomiris Drug Market (2025 - 2033) Size, Share & Trends Analysis Report By Indication (Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)), By End Use (Adult, Pediatric), By Distribution Channel, And Segment Forecasts
- Report Summary
- Table of Contents
- Segmentation
- Methodology
- Download FREE Sample
-
Download Sample Report
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. End Use
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Ultomiris Drug Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. U.S. Ultomiris Drug Market: Indication Business Analysis
4.1. Indication Market Share, 2024 & 2033
4.2. Indication Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
4.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
4.4.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, 2021 - 2033 (USD Million)
4.5. Atypical Hemolytic Uremic Syndrome (aHUS)
4.5.1. Atypical Hemolytic Uremic Syndrome (aHUS) Market, 2021 - 2033 (USD Million)
4.6. Generalized Myasthenia Gravis (gMG)
4.6.1. Generalized Myasthenia Gravis (gMG) Market, 2021 - 2033 (USD Million)
4.7. Neuromyelitis Optica Spectrum Disorder (NMOSD)
4.7.1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, 2021 - 2033 (USD Million)
Chapter 5. U.S. Ultomiris Drug Market: End Use Business Analysis
5.1. End Use Market Share, 2024 & 2033
5.2. End Use Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
5.4. Adult
5.4.1. Adult Market, 2021 - 2033 (USD Million)
5.5. Pediatric
5.5.1. Pediatric Market, 2021 - 2033 (USD Million)
Chapter 6. U.S. Ultomiris Drug Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2024 & 2033
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
6.6. Online Pharmacies
6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Alexion Pharmaceuticals (AstraZeneca)
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 U.S. Ultomiris Drug market, by indication, 2021 - 2033 (USD Million)
Table 4 U.S. Ultomiris Drug market, by end use, 2021 - 2033 (USD Million)
Table 5 U.S. Ultomiris Drug market, by distribution channel, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Ultomiris Drug market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and application outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Ultomiris Drug market dynamics
Fig. 12 Ultomiris Drug market: Porter’s five forces analysis
Fig. 13 Ultomiris Drug market: PESTLE analysis
Fig. 14 Indication market, 2021 - 2033 (USD Million)
Fig. 15 Paroxysmal Nocturnal Hemoglobinuria (PNH) market, 2021 - 2033 (USD Million)
Fig. 16 Atypical Hemolytic Uremic Syndrome (aHUS) market, 2021 - 2033 (USD Million)
Fig. 17 Generalized Myasthenia Gravis (gMG) market, 2021 - 2033 (USD Million)
Fig. 18 Neuromyelitis Optica Spectrum Disorder (NMOSD) market, 2021 - 2033 (USD Million)
Fig. 19 End Use market, 2021 - 2033 (USD Million)
Fig. 20 Adult market, 2021 - 2033 (USD Million)
Fig. 21 Pediatric market, 2021 - 2033 (USD Million)
Fig. 22 Distribution Channel market, 2021 - 2033 (USD Million)
Fig. 23 Hospital Pharmacies market, 2021 - 2033 (USD Million)
Fig. 24 Retail Pharmacies market, 2021 - 2033 (USD Million)
Fig. 25 Online Pharmacies market, 2021 - 2033 (USD Million)
Fig. 26 Company market position analysis
Fig. 27 Strategic framework
Get Free Sample Report
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
Trusted market insights - try a free sample
See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.
